[Effectiveness and safety of drug combination therapy in patients with advanced primary open-angle glaucoma].

Purpose: To study the hypotensive effectiveness and safety of Bimoptic Plus (bimatoprost 0.03% + timolol 0.5%) in patients with developed primary open-angle glaucoma (POAG).

Mitochondria-targeted antioxidant SkQ1 reverses glaucomatous lesions in rabbits.

Glaucoma is the main cause of irreversible blindness worldwide. This disease is characterized by apoptosis of retinal ganglion cells (RGC) and visual field loss that seems to be related to elevated intraocular pressure (IOP). Several lines of evidences have implicated the crucial role of mitochondrial dysfunction in the pathogenesis of glaucoma.

[Oscillatory potentials in the diagnosis of glaucoma optic neuropathy].

This study proposes new, original methods for diagnosis of glaucoma optic neuropathy--oscillatory potentials (OP) in an electroretinogram (ERG) to a long-term stimulus and in the 30 Hz flicker ERG (with identification of OP at frequencies of 80 to 120 Hz). Twenty-three patients (46 years) aged 40 to 65 years with primary open-angle glaucoma were examined. OP in the 30 Hz flicker ERG (01 and 02) and that in the ERG ON-response to a long-term stimulus have a similar origin and are linked with the light ON-channels of the retinal cone system.

Mitochondria-targeted plastoquinone derivatives as tools to interrupt execution of the aging program. 4. Age-related eye disease. SkQ1 returns vision to blind animals.

Mitochondria-targeted cationic plastoquinone derivative SkQ1 (10-(6'-plastoquinonyl) decyltriphenylphosphonium) has been investigated as a potential tool for treating a number of ROS-related ocular diseases. In OXYS rats suffering from a ROS-induced progeria, very small amounts of SkQ1 (50 nmol/kg per day) added to food were found to prevent development of age-induced cataract and retinopathies of the eye, lipid peroxidation and protein carbonylation in skeletal muscles, as well as a decrease in bone mineralization. Instillation of drops of 250 nM SkQ1 reversed cataract and retinopathies in 3-12-month-old (but not in 24-month-old) OXYS rats.